Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer.
about
Early experience with novel immunomodulators for cancer treatmentDifferential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation.The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure.Comparison of HER2 status by fluorescence in situ hybridisation and immunohistochemistry in gastric cancer.Met-related receptor tyrosine kinase Ron in tumor growth and metastasis.Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape.HER2 gene status in primary breast cancers and matched distant metastasesBiomarkers in migraine: their promise, problems, and practical applications.Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patientsDiscovery of Novel Human Epidermal Growth Factor Receptor-2 Inhibitors by Structure-based Virtual Screening.Overview of major classes of plant-derived anticancer drugsFunctional PET imaging in cancer drug development.RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer.Functional selectivity of EGF family peptide growth factors: implications for cancer.Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer.HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.Pharmacogenetics of chemotherapy efficacy in breast cancer.Intra-CSF administration of chemotherapy medications.Personalized medicine policy challenges: measuring clinical utility at point of care.Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique.A Tri-part Protein Complementation System Using Antibody-Small Peptide Fusions Enables Homogeneous Immunoassays.Immediate Reconstruction in Inflammatory Breast Cancer: Challenging Current Care.Response to trastuzumab by HER2 expressing breast tumour xenografts is accompanied by decreased Hexokinase II, glut1 and [18F]-FDG incorporation and changes in 31P-NMR-detectable phosphomonoesters.Investigating the structural biofunctionality of antibodies conjugated to magnetic nanoparticles.IMPLICATIONS OF GLOBAL PRICING POLICIES ON ACCESS TO INNOVATIVE DRUGS: THE CASE OF TRASTUZUMAB IN SEVEN LATIN AMERICAN COUNTRIES.First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimization analysis.Trastuzumab in HER2-positive metastatic gastric cancer: profile report.
P2860
Q28241744-C6D4629A-1614-4458-A791-E50587FD7B97Q33291042-40B9B1A6-3966-4C33-86EA-A157AAD126C5Q33595716-BAFAC99A-DEC8-4629-B94C-CE3F6061CFE7Q33799233-CA1CF126-34D9-402E-8D2C-CC92C03569BBQ33916081-71D5D264-374C-4E7A-AF4A-A07F16BF7F42Q33920097-D08D7C2A-283B-491C-A13D-6DD2EB63194EQ35906294-65117A51-94B1-49D2-BFDF-0D0230878102Q36546349-10CE01D0-5591-4E3A-9341-6526FB59DB8CQ36643014-549C7D8F-8865-4BB5-8C3B-009AD5CCDDACQ36733140-D8D20D0B-A295-4DE0-BE74-85D6D92CE4ABQ36735506-78915EE5-5F12-4624-834C-A9E64AEA75F3Q36768305-89A41C60-A816-4622-89A8-8971CF8D2B6DQ37134454-3E12F2CB-1F25-4119-8746-532CA4809A0EQ37149729-E0BFF94B-E5A1-45EE-A2DD-E3623C6DFC56Q37360194-BDDDCD1D-F546-4A9D-9C3F-6D610CEF9560Q37381593-0CCB6B5B-2FDA-441B-82BC-638CF7197028Q38003703-9A586D78-D4A3-4D06-BFBF-43997A79A64DQ38015719-1B237965-88AA-41CA-AE54-5379CA0DCE99Q38027568-6719B44C-614E-4003-B168-071E3EF329E3Q38084203-DBB43290-429D-44D2-A63F-354519A87BBDQ38642011-9A5A413C-8F5B-42D3-AB26-1218F8CDC0BAQ38957313-CF394607-FB9F-4846-9717-7DE873FEDE9AQ39239280-A58BD792-8880-4DD4-868D-35F5C0EF7001Q39650591-615A95C0-8CEF-44C4-9FC6-A8C1EE91EED0Q41728685-38700DEA-F73B-4513-8CA8-584D2AA4372DQ50760615-032EEDB6-34DB-412E-9C82-558D7988DDEEQ54569855-B5DDE395-00DD-4289-935C-F03BB59A3052
P2860
Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Trastuzumab: a review of its u ...... and early-stage breast cancer.
@ast
Trastuzumab: a review of its u ...... and early-stage breast cancer.
@en
type
label
Trastuzumab: a review of its u ...... and early-stage breast cancer.
@ast
Trastuzumab: a review of its u ...... and early-stage breast cancer.
@en
prefLabel
Trastuzumab: a review of its u ...... and early-stage breast cancer.
@ast
Trastuzumab: a review of its u ...... and early-stage breast cancer.
@en
P1433
P1476
Trastuzumab: a review of its u ...... and early-stage breast cancer.
@en
P2093
Susan J Keam
P2860
P304
P356
10.2165/00003495-200666040-00005
P577
2006-01-01T00:00:00Z
P6179
1048351038